Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05851391

buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest

RESTORE is a randomized clinical trial investigating the safety and feasibility of using EEG treatment targets (burst suppression vs. seizure suppression) for post-cardiac arrest refractory status epilepticus treatment.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Zuckerberg San Francisco General Hospital

San Francisco, California, 94110, United States

Location status: Recruiting

Location contact

Edilberto Amorim, MD

CONTACT

About this study

Rationale: Seizures emerge as a complication of hypoxic-ischemic brain injury in near a third of patients successfully resuscitated from cardiac arrest. Seizures post-cardiac arrest can be refractory to treatment with anti-seizure medications and anesthetics may be used for refractory status epilepticus control. Anesthetic treatment guided by continuous EEG can target burst suppression or seizure suppression, however it is not known which strategy is superior for achieving PCARSE control.

Objective: determine the safety and feasibility of post-cardiac arrest refractory status epilepticus (PCARSE) treatment using EEG goals for intravenous anesthetic titration (burst suppression vs. seizure suppression).

Clinical Trial Phase: II

Study Design: prospective, randomized, open-label, blinded end-point, concurrently-controlled, parallel arms design clinical trial.

Study Period: two years

Study Population: unconscious cardiac arrest survivors with return of spontaneous circulation who develop post-cardiac arrest refractory status epilepticus (PCARSE).

Interventions: anesthetic use targeting burst suppression vs. seizure suppression on EEG for 24 hours. Intervention maybe repeated using the dame EEG target once in case of PCARSE recurrence.

Sample Size: 30 subjects randomized in a 1:1 ratio to either burst suppression or seizure suppression EEG targets.

Primary Endpoints: Safety and feasibility of seizure control using burst suppression or seizure suppression EEG targets for PCARSE treatment.

Secondary Endpoints: Seizure recurrence incidence, time to seizure recurrence, number and dose of anti-seizure medication and anesthetic needed for PCARSE control, Death or disability according to the Cerebral Performance Category at Discharge (30 days), and Death or disability according to the modified Rankin Scale at Discharge (30 days).

Risks: Participants receiving anesthetics for PCARSE treatment will be monitored for hypotension, propofol infusion syndrome, and hypertriglyceridemia. Patients with PCARSE are at high risk for death and prolonged hospital stays.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years old
  • Non-traumatic, out-of-hospital cardiac arrest
  • Comatose on admission - defined as not following commands
  • Return of spontaneous circulation (ROSC) within less than 45 minutes
  • Admission to the intensive care unit
  • Diagnosis of post-cardiac arrest refractory status epilepticus confirmed with continuous

EEG monitoring within 7 days from ROSC

Exclusion criteria

  • Acute cerebral hemorrhage or infarction
  • Pregnancy
  • Prisoners

Treatment and study plan

Burst Suppression EEG Target Intravenous Anesthesia

Drug

The objective of the burst suppression EEG target is to stop seizures by titrating the anesthetic infusion to suppress most of the EEG background (>50% suppressed/attenuated). After this 24-hour period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.

Seizure Suppression EEG Target Intravenous Anesthesia

Drug

is to stop seizures by titrating the anesthetic infusion without suppressing most of the EEG background. This target would be continued for 24 hours. After this 24-hours period, this target would be continued for 24 hours. The anesthetic will then be tapered under EEG monitoring. In case of PCARSE recurrence, the intervention with the same target will be re-initiated for another cycle of 24 hours.

Primary outcomes

  1. Post-cardiac arrest refractory status epilepticus control

    Time frame: 48 hours

    Continuous EEG will be monitored to determine time to PCARSE recurrence during the anesthetic maintenance and anesthetic weaning phase (combined)

Secondary outcomes

  1. Seizure recurrence incidence and duration (burden)

    Time frame: 24-48 hours

    Presence of seizures on EEG after initiation of anesthetic maintenance phase

  2. Neurological Function at Discharge (CPC: Cerebral Performance Category)

    Time frame: 30 days

    Cerebral Performance Category score at Discharge

  3. Neurological Function at Discharge (mRS: modified Ranking Scale)

    Time frame: 30 days

    modified Rankin Scale score at Discharge

  4. Neurological Function 90 days (CPC: Cerebral Performance Category)

    Time frame: 90 days

    Cerebral Performance Category score at 90 days

  5. Neurological Function 90 days (mRS: modified Ranking Scale)

    Time frame: 90 days

    modified Rankin Scale score at Discharge

  6. Neurological Function 180 days (mRS: modified Ranking Scale)

    Time frame: 180 days

    modified Rankin Scale score at Discharge

  7. Neurological Function180 days (mRS: modified Ranking Scale)

    Time frame: 180 days

    modified Rankin Scale score at Discharge

  8. PCARSE Treatment Intensity

    Time frame: 24-48 hours

    Number of anti-seizure medications and anesthetics used for PCARSE control after initiation of anesthetic maintenance phase and prior to weaning

  9. Seizure recurrence incidence and duration (burden)

    Time frame: 24-48 hours

    Presence of seizures on EEG after initiation of anesthetic weaning phase

  10. PCARSE Treatment Intensity

    Time frame: 24-48 hours

    Dose of anti-seizure medications and anesthetics used for PCARSE control after initiation of anesthetic maintenance phase and prior to weaning

Study contacts

Contact information is provided by the study sponsor or research team.

Edilberto Amorim, MD

CONTACT

[email protected]

628-206-3203

Kevin Bao

CONTACT

[email protected]

(415)514-2120

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • The ZOLL Foundation

Registry information

Official study title

buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest (RESTORE)

Acronym: RESTORE

Important dates

Study start
2023
Primary completion
2026
Study completion
2027
First posted
May 9, 2023
Registry last updated
May 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.